| 51 |
29237391 | Utility of Pooled Cryopreserved Human Enterocytes as an In vitro Model for Assessing Intestinal Clearance and Drug-Drug Interactions. | 2018 |
1 |
| 52 |
29338933 | Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. | 2018 Feb |
1 |
| 53 |
29498947 | Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. | 2018 May |
1 |
| 54 |
29695615 | Metabolism of a 5HT6 Antagonist, 2-Methyl-1-(Phenylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzo[d]imidazole (SAM-760): Impact of Sulfonamide Metabolism on Diminution of a Ketoconazole-Mediated Clinical Drug-Drug Interaction. | 2018 Jul |
1 |
| 55 |
29749631 | Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety. | 2018 Nov |
1 |
| 56 |
29851709 | Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety. | 2018 Aug |
1 |
| 57 |
30072626 | Exploring the Metabolism of Loxoprofen in Liver Microsomes: The Role of Cytochrome P450 and UDP-Glucuronosyltransferase in Its Biotransformation. | 2018 Aug 2 |
1 |
| 58 |
30087611 | Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug. | 2018 |
2 |
| 59 |
30283337 | The Modulatory Role of CYP3A4 in Dictamnine-Induced Hepatotoxicity. | 2018 |
4 |
| 60 |
27226420 | Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives. | 2017 Apr |
1 |
| 61 |
27273461 | Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults. | 2017 Jan |
2 |
| 62 |
27821711 | Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized. | 2017 Jan |
1 |
| 63 |
27836570 | Metabolic-induced cytotoxicity of diosbulbin B in CYP3A4-expressing cells. | 2017 Feb |
1 |
| 64 |
27859472 | Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. | 2017 Apr |
3 |
| 65 |
27939799 | The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo. | 2017 Apr |
1 |
| 66 |
28052338 | Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. | 2017 Jun |
1 |
| 67 |
28185143 | Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation. | 2017 Oct |
1 |
| 68 |
28238727 | Testosterone metabolism of equine single CYPs of the 3A subfamily compared to the human CYP3A4. | 2017 Jun |
1 |
| 69 |
28238899 | Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions. | 2017 Sep |
1 |
| 70 |
28442602 | Molecular Basis of Metabolism-Mediated Conversion of PK11195 from an Antagonist to an Agonist of the Constitutive Androstane Receptor. | 2017 Jul |
1 |
| 71 |
28503781 | Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. | 2017 Oct |
1 |
| 72 |
28912253 | Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions. | 2017 Dec |
2 |
| 73 |
28977209 | The use of aromatase inhibitors in boys with short stature: what to know before prescribing? | 2017 Jul-Aug |
1 |
| 74 |
29022184 | Effects of Ketoconazole on the Pharmacokinetics of Mifepristone, a Competitive Glucocorticoid Receptor Antagonist, in Healthy Men. | 2017 Oct |
2 |
| 75 |
25374256 | CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect. | 2016 Feb |
2 |
| 76 |
25737032 | Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking. | 2016 Aug |
2 |
| 77 |
26044116 | Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. | 2016 Feb |
2 |
| 78 |
26207435 | Characterization of midazolam metabolism in locusts: the role of a CYP3A4-like enzyme in the formation of 1'-OH and 4-OH midazolam. | 2016 |
1 |
| 79 |
26242379 | Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib. | 2016 Jan |
1 |
| 80 |
26294260 | Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor. | 2016 |
1 |
| 81 |
26385839 | Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions. | 2016 Mar |
1 |
| 82 |
26610396 | In vitro metabolism of the cyanotoxin cylindrospermopsin in HepaRG cells and liver tissue fractions. | 2016 Feb |
1 |
| 83 |
26655108 | Comparison of enzyme kinetics of warfarin analyzed by LC-MS/MS QTrap and differential mobility spectrometry. | 2016 Jan 1 |
1 |
| 84 |
26668209 | Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. | 2016 Mar |
2 |
| 85 |
26814638 | Membrane Interactions, Ligand-Dependent Dynamics, and Stability of Cytochrome P4503A4 in Lipid Nanodiscs. | 2016 Feb 23 |
2 |
| 86 |
26829173 | Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers. | 2016 Oct |
2 |
| 87 |
26956883 | Modulation of CYP3A4 activity alters the cytotoxicity of lipophilic phycotoxins in human hepatic HepaRG cells. | 2016 Jun |
1 |
| 88 |
27098526 | Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms. | 2016 Jun |
2 |
| 89 |
27113703 | The role of CYP 3A4 and 1A1 in amiodarone-induced hepatocellular toxicity. | 2016 Jun 24 |
1 |
| 90 |
27287938 | Chemically induced hepatotoxicity in human stem cell-induced hepatocytes compared with primary hepatocytes and HepG2. | 2016 Oct |
1 |
| 91 |
27402728 | CYP3A Specifically Catalyzes 1β-Hydroxylation of Deoxycholic Acid: Characterization and Enzymatic Synthesis of a Potential Novel Urinary Biomarker for CYP3A Activity. | 2016 Sep |
1 |
| 92 |
27450182 | Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib. | 2016 Oct |
2 |
| 93 |
27627192 | In Silico Predictions and In Vivo Results of Drug-Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate. | 2016 Sep |
1 |
| 94 |
24464299 | Effect of NIPRISAN® on CYP3A4 activity in vitro. | 2015 Mar |
1 |
| 95 |
25159194 | Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. | 2015 Feb |
1 |
| 96 |
25382218 | Optimized on-line enantioselective capillary electrophoretic method for kinetic and inhibition studies of drug metabolism mediated by cytochrome P450 enzymes. | 2015 Jun |
1 |
| 97 |
25424246 | Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes. | 2015 Jun |
1 |
| 98 |
25443889 | Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment. | 2015 Jun |
1 |
| 99 |
25470032 | An adaptive design to investigate the effect of ketoconazole on pharmacokinetics of GSK239512 in healthy male volunteers. | 2015 May |
1 |
| 100 |
25499431 | Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein. | 2015 Jan 15 |
2 |